Cincor Stock Analysis

CINC -  USA Stock  

USD 18.20  2.13  13.25%

The current price rise of Cincor Pharma could raise concerns from investors as the firm it trading at a share price of 18.20 on 113,000 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.72. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cincor Pharma partners.
Continue to Trending Equities.

Cincor Stock Analysis 

 
Refresh
The Cincor Pharma stock analysis report makes it easy to digest most publicly released information about Cincor Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cincor Stock analysis module also helps to analyze the Cincor Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Cincor Stock Analysis Notes

About 48.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts. Cincor Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Cincor Pharma please contact the company at 844-531-1834 or go to https://www.cincor.com.

Cincor Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cincor Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cincor Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cincor Pharma is way too risky over 90 days horizon
Cincor Pharma appears to be risky and price may revert if volatility continues
Cincor Pharma has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (26.83 M).
Cincor Pharma currently holds about 26.08 M in cash with (24.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.43.
Cincor Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from www.barrons.com: Yoshitsus IPO Takes the Lead for the Top Pop in 2022 - Barrons

Cincor Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cincor Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cincor Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cincor Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
11th of January 2022
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Unclassified Corporate Event
View

Cincor Profitablity

Cincor Pharma's profitability indicators refer to fundamental financial ratios that showcase Cincor Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Cincor Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cincor Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cincor Pharma's profitability requires more research than a typical breakdown of Cincor Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(1.04) (1.12) 
Return on Average Equity 1.24  1.23 
Return on Invested Capital 5.39  5.35 

Management Efficiency

As of January 23, 2022, Return on Average Assets is expected to decline to -1.12. In addition to that, Return on Average Equity is expected to decline to 1.23. As of January 23, 2022, Total Assets is expected to decline to about 27.4 M. In addition to that, Current Assets is expected to decline to about 27.4 MCincor Pharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share(5.77) (6.23) 
Tangible Assets Book Value per Share 7.25  6.46 
Tangible Asset Value30.8 M27.4 M

Technical Drivers

As of the 23rd of January, Cincor Pharma shows the risk adjusted performance of 0.1688, and Mean Deviation of 5.09. Cincor Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Cincor Pharma, which can be compared to its rivals. Please confirm Cincor Pharma maximum drawdown, and the relationship between the information ratio and downside variance to decide if Cincor Pharma is priced correctly, providing market reflects its regular price of 18.2 per share. Given that Cincor Pharma has jensen alpha of 1.5, we suggest you to validate Cincor Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Cincor Pharma Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Cincor Pharma more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Cincor Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cincor Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cincor Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cincor Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cincor Pharma Predictive Daily Indicators

Cincor Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cincor Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cincor Pharma Forecast Models

Cincor Pharma time-series forecasting models is one of many Cincor Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cincor Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cincor Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cincor Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cincor shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cincor Pharma. By using and applying Cincor Stock analysis, traders can create a robust methodology for identifying Cincor entry and exit points for their positions.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts. Cincor Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cincor Pharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module
Continue to Trending Equities. Note that the Cincor Pharma information on this page should be used as a complementary analysis to other Cincor Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Cincor Stock analysis

When running Cincor Pharma price analysis, check to measure Cincor Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cincor Pharma is operating at the current time. Most of Cincor Pharma's value examination focuses on studying past and present price action to predict the probability of Cincor Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cincor Pharma's price. Additionally, you may evaluate how the addition of Cincor Pharma to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Cincor Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cincor Pharma. If investors know Cincor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cincor Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cincor Pharma is measured differently than its book value, which is the value of Cincor that is recorded on the company's balance sheet. Investors also form their own opinion of Cincor Pharma's value that differs from its market value or its book value, called intrinsic value, which is Cincor Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cincor Pharma's market value can be influenced by many factors that don't directly affect Cincor Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cincor Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Cincor Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cincor Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.